Jubilant Ingrevia Q2 FY27 slides: EBITDA surges 51% YoY

Jubilant Ingrevia reported Q2 FY27 revenue of INR 1,394 crore, up 24% year over year, EBITDA of INR 221 crore, up 51%, and PAT of INR 111 crore, up 61%; EBITDA margin was 16%. Management maintained FY27 EBITDA guidance of INR 750–800 crore and expects to land near the upper end, while the company acquired a 40% stake in ZettaOne Technologies for INR 189.2 crore to enter electronics design and manufacturing. Shares rose 4.35% to $632.35 after the results; Vitamin B3 pricing pressure, agrochemical overcapacity in China, and lumpy CDMO revenue remain risks.

Analysis

The key underwriting question is whether Q2 marks durable mix and utilization gains or a cyclical realization rebound. H1 EBITDA of INR 431 crore leaves INR 319–369 crore needed in H2 to meet the INR 750–800 crore guide—below H1’s run rate—so the guide appears achievable even with some normalization. That reduces near-term downside from a merely softer Q3, but does not validate the longer-term growth aspiration.

Earnings quality is mixed: Specialty Chemicals supplies most EBITDA, while the sharp Chemical Intermediates improvement is partly from a weak comparison and relies on pricing benefits that may take time to follow the European competitor closure. Vitamin B3 price pressure and Chinese agrochemical overcapacity are offsets. Higher crude can support realizations but also raises input costs; monitor segment margins, not revenue growth alone. The INR 400–500 crore capex program makes utilization and cash conversion important confirmation points.

The ZettaOne stake offers optionality, not yet a reason to capitalize semiconductor growth into the chemicals valuation: it is a minority investment, and projected growth and margins are management claims until audited results and customer wins demonstrate contribution. The immediate positive reaction may discount some near-term improvement, while the more material catalyst—the European closure’s pricing effect—appears delayed. Contrarian risk is that investors extrapolate a strong quarter and pipeline potential into a smooth earnings trajectory despite lumpy CDMO conversion and segment-specific pricing exposure.

Key Decisions for Investors

• Favor a staged long in Jubilant Ingrevia on weakness rather than chase the post-results move; the H2 arithmetic gives guidance some cushion, but wait for Q3 evidence before underwriting sustained margin expansion. No ticker mapping or valuation data was supplied, so avoid a price target.
• Use Q3 and Q4 results as the 1–3 month checkpoints: track Specialty Chemicals margin, CDMO molecule conversion, Vitamin B3 realizations, and Acetyls volumes/pricing. Reassess the long thesis if EBITDA run-rate or guidance is cut, or if margins contract despite revenue growth.
• Treat ZettaOne as an alert, not a standalone catalyst trade. Upgrade its value only after disclosed customer wins, order conversion, and reported profitability substantiate the growth claims; verify the investment’s cash-flow and capital-allocation impact.
• The key 6–18 month upside catalyst is realization of European supply tightening; falsification would be no meaningful Acetic Anhydride pricing or volume improvement by early next calendar year. Also monitor free cash flow and asset utilization against the elevated capex plan.